207 related articles for article (PubMed ID: 11698713)
1. Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients.
Fätkenheuer G; Römer K; Kamps R; Salzberger B; Burger D
AIDS; 2001 Nov; 15(17):2334-5. PubMed ID: 11698713
[No Abstract] [Full Text] [Related]
2. Delavirdine increases drug exposure of ritonavir-boosted protease inhibitors.
Harris M; Alexander C; O'Shaughnessy M; Montaner JS
AIDS; 2002 Mar; 16(5):798-9. PubMed ID: 11964540
[No Abstract] [Full Text] [Related]
3. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
[TBL] [Abstract][Full Text] [Related]
4. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
[TBL] [Abstract][Full Text] [Related]
5. Saquinavir plus lopinavir/ritonavir versus amprenavir plus lopinavir/ritonavir for treating highly resistant patients in Brazil.
Tenore S; Ferreira PA; Diaz RS
J Acquir Immune Defic Syndr; 2008 Apr; 47(4):526-8. PubMed ID: 18332770
[No Abstract] [Full Text] [Related]
6. A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naive HIV-infected patients.
Harris M; Côté H; Ochoa C; Allavena C; Negredo E; Thorne A; Cahn P; Zala C; Raffi F; Clotet B; Singer J; Montaner J;
J Acquir Immune Defic Syndr; 2009 Mar; 50(3):335-7. PubMed ID: 19242263
[No Abstract] [Full Text] [Related]
7. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Arvieux C; Tribut O
Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
[TBL] [Abstract][Full Text] [Related]
8. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
Raguin G; Chêne G; Morand-Joubert L; Taburet AM; Droz C; Le Tiec C; Clavel F; Girard PM;
Antivir Ther; 2004 Aug; 9(4):615-25. PubMed ID: 15456093
[TBL] [Abstract][Full Text] [Related]
9. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.
Murphy RL; Brun S; Hicks C; Eron JJ; Gulick R; King M; White AC; Benson C; Thompson M; Kessler HA; Hammer S; Bertz R; Hsu A; Japour A; Sun E
AIDS; 2001 Jan; 15(1):F1-9. PubMed ID: 11192874
[TBL] [Abstract][Full Text] [Related]
10. New drugs in development.
Proj Inf Perspect; 1998 Sep; (25):8. PubMed ID: 11365851
[TBL] [Abstract][Full Text] [Related]
11. Benefits and risks of switching from protease inhibitors to nevirapine with stable background therapy in patients with low or undetectable viral load: a multicentre study.
De Luca A; Baldini F; Cingolani A; Di Giambenedetto S; Zaccarelli M; Tozzi V; Ammassari A; Murri R; Antinori A
AIDS; 2000 Jul; 14(11):1655-6. PubMed ID: 10983653
[No Abstract] [Full Text] [Related]
12. [Efavirenz--comprehensive status of studies].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():79-81. PubMed ID: 16385886
[No Abstract] [Full Text] [Related]
13. [Plasma levels following the switch from amprenavir to fosamprenavir in HIV-infected patients under antiretroviral treatment with lopinavir/ritonavir].
Delgado O; Riera M; Murillas J; Ventayol P
Enferm Infecc Microbiol Clin; 2008 Mar; 26(3):182-3. PubMed ID: 18358222
[No Abstract] [Full Text] [Related]
14. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study).
Breilh D; Pellegrin I; Rouzés A; Berthoin K; Xuereb F; Budzinski H; Munck M; Fleury HJ; Saux MC; Pellegrin JL
AIDS; 2004 Jun; 18(9):1305-10. PubMed ID: 15362663
[TBL] [Abstract][Full Text] [Related]
15. Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics.
Boffito M; Arnaudo I; Raiteri R; Bonora S; Sinicco A; Di Garbo A; Reynolds HE; Hoggard PG; Back DJ; Di Perri G
AIDS; 2002 Oct; 16(15):2081-3. PubMed ID: 12370509
[TBL] [Abstract][Full Text] [Related]
16. Report from the 16th Conference on Retroviruses and Opportunistic Infections. Lopinavir/r is superior to nevirapine in women who previously received single-dose nevirapine.
Feinberg J
J Watch AIDS Clin Care; 2009 Apr; 21(4):33. PubMed ID: 19544617
[No Abstract] [Full Text] [Related]
17. Amprenavir.
Adkins JC; Faulds D
Drugs; 1998 Jun; 55(6):837-42; discussion 843-4. PubMed ID: 9617598
[TBL] [Abstract][Full Text] [Related]
18. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
[TBL] [Abstract][Full Text] [Related]
19. Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics.
De Luca A; Baldini F; Cingolani A; Di Giambenedetto S; Hoetelmans RM; Cauda R
J Acquir Immune Defic Syndr; 2004 Apr; 35(4):359-66. PubMed ID: 15097152
[TBL] [Abstract][Full Text] [Related]
20. Switch study of nevirapine.
AIDS Patient Care STDS; 2000 Dec; 14(12):672. PubMed ID: 11187109
[No Abstract] [Full Text] [Related]
[Next] [New Search]
